908 Devices(NASDAQ) MASS

908 Devices Inc. makes tools that identify unknown chemicals instantly. These tools help emergency workers find dangerous drugs and hazardous materials. The technology shrinks large laboratory equipment into battery-powered portable machines.

Small Tools for Big Threats

• Handheld Devices: Portable battery-powered tools used for chemical analysis and hazard identification including mass spectrometry (Mass Spec) and fourier transform infrared (FTIR) technology; accounted for 69% of total revenue for the six months ended June 30, 2026.
• Recurring Revenue: Sales of single-use swab samplers, software subscriptions, and service contracts for the existing fleet of devices; made up 30% of total revenue in the first half of 2026.
• Contract Services: Engineering and development services provided to the U.S. government and commercial partners for specialized technology programs.

Shifting Focus and Scaling Up

• Completed the sale of the Desktop Portfolio to Repligen on March 4, 2025, to focus the business on handheld devices.
• Acquired NIRLab to add near-infrared spectroscopy tools that identify chemicals through material packaging.
• Launched the VipIR handheld analyzer, which combines three light-based technologies to identify hazardous liquids and powders in one test.
• Expanded sales efforts among U.S. federal and state authorities to address the fentanyl and counterfeit pharmaceutical crisis.

Lab Power in Your Hand

The company uses proprietary mass spectrometry to detect chemicals at levels 1,000 times below a lethal dose. By automating complex data analysis with machine learning, these tools give first responders actionable answers without needing a laboratory scientist.

The Numbers Behind the Mission

• Product revenue grew 31% to $23.7 million during the six months ended June 30, 2026, driven by higher device shipments.
• Service and contract revenue decreased 14% to $5.7 million in the first half of 2026 due to a funding-related pause from a major defense customer.
• Cumulative product placements for handheld devices reached 4,101 units by June 30, 2026, up from 3,336 units in the prior year.
• Net loss from continuing operations was $23.8 million for the six-month period ended June 30, 2026.

Evolution of the Business

908 Devices has transitioned into a dedicated handheld diagnostics company by divesting its desktop laboratory business. Its growth depends on expanding its device fleet and increasing recurring sales of consumables and software to government and industrial users.